DOI: 10.3724/SP.J.1264.2011.00018

Chinese Journal of Multiple Organ Diseases in the Elderly (中华老年多器官疾病杂志) 2011/10:4 PP.357-361

Effects of telmisartan on the expression of matrix metalloproteinase-13 and its tissue inhibitor-1 and insulin resistance in nonalcoholic steatohepatitis rat model

Objective To study the effects of telmisartan on matrix metalloproteinase-13 (MMP-13) and tissue inhibitor of metalloproteinase-1 (TIMP-1) expressions and insulin resistance in rat model of nonalcoholic steatohepatitis (NASH). Methods Thirty male SD rats were randomized into normal control group, NASH model group and telmisartan intervention group. The rats were given standard food in normal control group, while high fat diet for 16 weeks in the other two groups to induce NASH. In telmisartan intervention group, telmisartan[5 mg/(kg·d) ] was adminstrated intragastrically for 4 weeks since the 12th week. All animals were sacrificed at 16 weeks. Serum levels of alanine aminotransferase(ALT), aspartate transaminase(AST), fasting blood glucose (FBG) and fasting insulin (FINS) were detected. Insulin sensitivity was evaluated by homeostasis model assessment of insulin resistance(HOMA-IR). Western blot and RT-PCR were used to measure TIMP-1 and MMP-13 expressions in hepatic tissue. Histological observation and immunohistochemical staining of α-smooth muscle actin(α-SMA) were also performed. Results Serum levels of ALT, AST, FPG, FINS and HOMA-IR were significantly higher in NASH group than in normal control group (P<0.01=. Compared with NASH group, serum levels of ALT, FPG, FINS and HOMA-IR decreased significantly(P<0.01=, and AST level also decreased, but with no signifi-cance(P>0.05). Telmisartan improved significantly hepatic inflammation and fibrosis(P<0.01=, decreased HOMA-IR significantly(P<0.01=, reduced expresseions of α-SMA and TIMP-1, and increased expressions of MMP-13 in hepatic tissue(P<0.01). Conclusion Telmisartan can improve insulin resistance and prevent hepatic fibrosis in NASH rats.

Key words:rats,hepatitis, nonalcoholic,matrix metalloproteinase 13,telmisartan,actin

ReleaseDate:2014-07-21 15:56:25

[1] Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty con-nection[J]. Hepatology, 2010, 51(5): 1820-1832 .

[2] Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease[J]. Curr Opin Gastroenterol, 2008, 24(3): 320-327.

[3] Ueki M, Koda M, Yamamoto S, et al. Preventive and therapeutic effects of angiotensin Ⅱ type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats[J]. J Gastroenterol, 2006, 41(10): 996-1004.

[4] Sugimoto K, Qi NR, Kazdova L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis[J]. Hypertension, 2006, 47(5): 1003-1009.

[5] Schwimmer JB, Behling C, Newbury R, et al. Histopa- thology of pediatric nonalcoholic fatty liver dis-ease[J]. Hepatology, 2005, 42(3): 641-649.

[6] Mancini FP, Lanni A, Sabatino L, et al. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats[J]. FEBS Lett, 2001, 491(1-2): 154-158.

[7] Varela-Rey M, Embade N, Ariz U, et al. Non-alcoholic steatohepatitis and animal models: under-standing the human disease[J]. Int J Biochem Cell Biol, 2009, 41(5): 969-976.

[8] 徐正婕, 范建高, 王国良, 等. 高脂饮食致大鼠非酒精性脂肪性肝炎肝纤维化模型[J]. 世界华人消化杂志, 2002, 10(4): 392-396.

[9] Yan S, Chen GM, Yu CH, et al. Expression pattern of matrix metalloproteinases-13 in a rat model of alcoholic liver fibrosis[J]. Hepatobiliary Pancreat Dis Int, 2005, 4(4): 569-572.

[10] Yoshiji H, Kuriyama S, Yoshii J, et al. Tissue in-hibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse[J]. Hepatology, 2002, 36(4 pt 1): 850-860.

[11] Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells[J]. Sem Liver Dis, 2001, 21(3): 373-384.

[12] Yoshiji H, Kuriyama S, Fukui H. Blockade of renin- angio-tensin system in antifibrotic therapy[J]. J Gastroenterol Hepatol, 2007, 22(Suppl 1): S93-S95.